Crossmark

Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Crossref DOI link: https://doi.org/10.1007/s13300-021-01014-0

Published Online: 2021-02-16

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Seino, Hiroaki http://orcid.org/0000-0003-4690-9722
Funding

Funding for this research was provided by:

Taisho Pharmaceutical Co. Ltd.
License Information

Text and Data Mining valid from 2021-02-16

Version of Record valid from 2021-02-16
More Information

Article History

Received: 23 December 2020

Accepted: 27 January 2021

First Online: 16 February 2021

Change Date: 13 September 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13300-021-01123-w

Updates are available Correction dated 2021-09-13

Click to view Correction: https://doi.org/10.1007/s13300-021-01123-w